As healthcare reform advances, experts say, dermatologists face mounting pressure to prove their mettle to insurance exchanges and accountable care organizations (ACOs).
New prognostic factors may help to predict survival in patients diagnosed with thin melanoma, recent study findings suggest.
The asthma drug omalizumab may provide symptom relief to patients with chronic idiopathic urticaria, results of a recently published study suggest.
Genentech has announced that its phase 3 coBRIM study, evaluating the safety and efficacy of a combination of cobimetinib and vemurafenib for the treatment of melanoma, has met its primary endpoint.
As a medical professional in the field of dermatology and aesthetics your time is valuable and there are only so many hours in a day. So the million-dollar question is: Beyond providing quality care for your patients and relying on voluntary referral sources, how you can maximize the potential of your practice?